<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04317586</url>
  </required_header>
  <id_info>
    <org_study_id>79</org_study_id>
    <nct_id>NCT04317586</nct_id>
  </id_info>
  <brief_title>Trident II Revision Outcomes Study</brief_title>
  <official_title>A Prospective, Post-market, Multi-center Evaluation of the Clinical Outcomes of the Trident II Acetabular Shell in a Revision Indication</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stryker Orthopaedics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stryker Orthopaedics</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to review the performance and success rate of an FDA approved&#xD;
      cementless hip replacement part called the Trident II Tritanium Acetabular Shell. The study&#xD;
      will specifically look at the need to revise the hip replacement after 5 years. This will be&#xD;
      compared to how much this happens in patients who have hip replacement with similar&#xD;
      cementless acetabular shells.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 23, 2020</start_date>
  <completion_date type="Anticipated">April 2035</completion_date>
  <primary_completion_date type="Anticipated">April 2030</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of cases that had successful revision with Trident II Acetabular Shell of a Total Hip Replacement</measure>
    <time_frame>5 years</time_frame>
    <description>To demonstrate, through absence of revision for aseptic loosening at five years postoperative, that acetabular revision with the Trident II Acetabular Shell provides clinical results comparable to similar acetabular components for revision indications.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiographic Radiolucency</measure>
    <time_frame>6 weeks, 3-6 months, 1, 2, 5, 7, 10 years</time_frame>
    <description>Radiolucency in at least 50% of an acetabular component zone and measuring at least 1 mm in width is defined as radiolucency present.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic Migration</measure>
    <time_frame>6 weeks, 3-6 months, 1, 2, 5, 7, 10 years</time_frame>
    <description>Migration of the device will be measured by millimeters.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">347</enrollment>
  <condition>Arthroplasty, Hip Revision</condition>
  <arm_group>
    <arm_group_label>Trident II Tritanium Acetabular Shell for Revision</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Trident II Tritanium Acetabular Shell for Revision</intervention_name>
    <description>A hemispherical acetabular shell indicated for cementless application in a previously failed total hip arthroplasty (THA)</description>
    <arm_group_label>Trident II Tritanium Acetabular Shell for Revision</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        A. Patient has signed an IRB approved, study specific Informed Patient Consent Form.&#xD;
&#xD;
        B. Patient is a male or non-pregnant female age 18-85 years of age at the time of study&#xD;
        device implantation.&#xD;
&#xD;
        C. Patient is a candidate for a revision of a failed acetabular component with a cementless&#xD;
        acetabular component.&#xD;
&#xD;
        D. Patient is willing and able to comply with postoperative scheduled clinical and&#xD;
        radiographic evaluations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        E. Patient has a Body Mass Index (BMI) &gt; 45. F. Patient is diagnosed with Inflammatory&#xD;
        Arthritis. G. Patient has a non-Stryker retained stem. H. Patient has an active or&#xD;
        suspected latent infection in or about the affected hip joint at time of study device&#xD;
        implantation.&#xD;
&#xD;
        I. Patient has a mental or neuromuscular disorder which would create an unacceptable risk&#xD;
        of prosthesis instability, prosthesis fixation failure, or complications in postoperative&#xD;
        care.&#xD;
&#xD;
        J. Patient has compromised bone stock which cannot provide adequate support and/or fixation&#xD;
        to the prosthesis.&#xD;
&#xD;
        K. Patient is diagnosed with a systemic disease (e.g. Lupus Erythematosus) or a metabolic&#xD;
        disorder (e.g. Paget's Disease) leading to progressive bone deterioration.&#xD;
&#xD;
        L. Patient is immunologically suppressed or receiving steroids in excess of normal&#xD;
        physiological requirements (e.g. &gt; 30 days). M. Patient has a known sensitivity to device&#xD;
        materials. N. Patient is a prisoner.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alice Cruz</last_name>
    <phone>201-831-5859</phone>
    <email>alice.cruz@stryker.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Southeast Orthopedic Specialists</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andres Cedeno</last_name>
      <phone>904-328-6711</phone>
      <email>andresacede@gmail.com</email>
    </contact>
    <investigator>
      <last_name>John Redmond, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lafayette General Orthopedic Center</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <zip>70506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory Sistrunk</last_name>
      <phone>337-571-0069</phone>
      <email>gjsistrunk@lgh.org</email>
    </contact>
    <investigator>
      <last_name>Paul C. Buzhardt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily-Ann Berner</last_name>
      <phone>617-643-3513</phone>
      <email>EABERNER@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Santiago Lozano-Calderon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Barthel</last_name>
      <email>Thomas.Barthel@umassmed.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew Deren, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital Research Institute</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shalinee Mylvaganam</last_name>
      <phone>248-551-0194</phone>
      <email>Shalinee.Mylvaganam@beaumont.org</email>
    </contact>
    <investigator>
      <last_name>Mark Karadsheh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Perry Greene III, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffrey Devitt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Orthopaedic &amp; Fracture Clinic, P.A.</name>
      <address>
        <city>Mankato</city>
        <state>Minnesota</state>
        <zip>56001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerald Berberick, OPA-C</last_name>
      <phone>507-386-6600</phone>
      <email>gerryberberick.ofc@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Kyle C Swanson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OrthoNY</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie McCann</last_name>
      <phone>518-453-9088</phone>
      <phone_ext>3162</phone_ext>
      <email>smccann@orthony.com</email>
    </contact>
    <investigator>
      <last_name>Frank Congiusta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacob Draper</last_name>
      <phone>801-213-3366</phone>
      <email>jacob.draper@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Lucas Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeremy Gililland, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 12, 2020</study_first_submitted>
  <study_first_submitted_qc>March 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2020</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

